RESPIRATORY HEALTH · KASDAP HEALTHCARE
Air pollution, allergens, and occupational hazards have made respiratory disorders a public health crisis in India. This guide covers the medicines, delivery systems, and clinical considerations essential for managing breathing disorders.
Respiratory Health in India: A Growing Crisis
India faces a significant and worsening respiratory health challenge. Ranked among the most polluted countries globally, with 22 of the world's 30 most polluted cities, India's air quality crisis directly translates into a respiratory disease epidemic. Asthma affects an estimated 30 million Indians, COPD afflicts over 15 million, and allergic rhinitis is estimated to affect 20–30% of the urban population.
Beyond pollution, India's diverse geography — from high-altitude regions to tropical coastal areas — creates unique respiratory challenges. Biomass fuel burning in rural households, occupational dust exposure in industrial workers, and seasonal allergen peaks in agricultural regions all contribute to the respiratory disease burden.
Bronchodilators: Opening the Airways
Short-Acting Beta-2 Agonists (SABAs)
Salbutamol (Albuterol) is the most widely used SABA globally and in India. It provides rapid bronchodilation within minutes, making it the rescue inhaler of choice in acute asthma and COPD exacerbations. Available as pressurised metered-dose inhalers (pMDIs), nebulisation solutions (respules), and oral formulations, Salbutamol's versatility makes it essential across all levels of the healthcare system.
Long-Acting Beta-2 Agonists (LABAs)
Formoterol and Salmeterol provide sustained bronchodilation (12 hours or more), making them suitable for maintenance therapy in asthma and COPD. They are always used in combination with inhaled corticosteroids (ICS) in asthma management — never as monotherapy — as ICS/LABA combinations address both bronchoconstriction and airway inflammation.
Long-Acting Muscarinic Antagonists (LAMAs)
Tiotropium, Umeclidinium, and Glycopyrronium are the primary bronchodilator class for COPD maintenance therapy. They reduce air trapping, improve exercise tolerance, and decrease exacerbation frequency. Triple therapy (ICS + LABA + LAMA) is increasingly recommended for patients with frequent exacerbations.
Inhaled Corticosteroids: The Anti-Inflammatory Foundation
Inhaled corticosteroids are the cornerstone of asthma maintenance therapy, reducing airway inflammation, preventing exacerbations, and protecting against long-term airway remodelling. Key agents include:
- Budesonide: Most widely used ICS in India, available as pMDI, Rotacap, and Respule. Budesonide Respules are particularly important in paediatric asthma management via nebulisation.
- Beclomethasone dipropionate: Available as extra-fine particle formulation for improved peripheral airway deposition
- Fluticasone propionate and Fluticasone furoate: High-potency ICS agents used in moderate-to-severe asthma
- Ciclesonide: Pro-drug activated in the lungs, with minimal systemic bioavailability
Antihistamines: Managing Allergic Conditions
Second-Generation Antihistamines
Cetirizine, Levocetirizine, Fexofenadine, Loratadine, and Desloratadine have largely replaced first-generation antihistamines (Chlorpheniramine, Diphenhydramine) in clinical practice due to their non-sedating profiles and longer duration of action. They are first-line for allergic rhinitis, urticaria, and atopic dermatitis.
Intranasal Corticosteroids
Fluticasone, Mometasone, and Budesonide nasal sprays are the most effective pharmacological treatment for allergic rhinitis, superior to oral antihistamines for nasal congestion. They are safe for long-term use with minimal systemic absorption.
Mucolytics and Expectorants
Mucolytics reduce the viscosity of respiratory secretions, improving mucociliary clearance and facilitating expectoration. Key agents include:
- Ambroxol: The most widely prescribed mucolytic in India, also with mild anti-inflammatory and local anaesthetic properties
- Bromhexine: Precursor to Ambroxol, available in multiple formulations
- Acetylcysteine (NAC): Powerful mucolytic used in COPD, bronchiectasis, and as an antidote for paracetamol overdose
- Guaifenesin: The most common expectorant in combination cough preparations
Specialty Respiratory Dosage Forms
The respiratory therapeutic segment is unique in its heavy reliance on specialty drug delivery systems that require precise manufacturing to deliver consistent pulmonary drug deposition:
- Pressurised Metered-Dose Inhalers (pMDIs): Require patient coordination; spacer devices improve delivery efficiency
- Dry Powder Inhalers (DPIs) including Rotacaps: Breath-actuated, requiring adequate inspiratory flow; no coordination issue
- Nebulisation Solutions (Respules): Ideal for paediatric patients, the elderly, and acute exacerbations requiring high drug doses
- Nasal Sprays: For intranasal drug delivery in rhinitis and nasal polyps
Kasdap Healthcare's Respiratory & Allergy Portfolio
Kasdap Healthcare offers a comprehensive respiratory and allergy range including bronchodilator inhalers, ICS combinations, Respules, Rotacaps, antihistamines, mucolytics, and nasal preparations — all manufactured under WHO-GMP aligned standards and distributed through our pan-India network.
Explore Kasdap's Respiratory & Allergy product range
